Alsuma is a drug owned by Meridian Medical Technologies Inc Sub King Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 26, 2027. Details of Alsuma's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7811254 | Autoinjector with needle depth adapter |
Aug, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Alsuma's patents.
Latest Legal Activities on Alsuma's Patents
Given below is the list of recent legal activities going on the following patents of Alsuma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Oct, 2022 | US7811254 |
| 11.5 yr surcharge- late pmt w/in 6 mo, Large Entity | 12 Oct, 2022 | US7811254 |
| Maintenance Fee Reminder Mailed Critical | 30 May, 2022 | US7811254 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Mar, 2018 | US7811254 |
| Change in Power of Attorney (May Include Associate POA) Critical | 10 Jun, 2016 | US7811254 |
| Email Notification Critical | 10 Jun, 2016 | US7811254 |
| Correspondence Address Change Critical | 09 Jun, 2016 | US7811254 |
| Correspondence Address Change Critical | 29 Aug, 2014 | US7811254 |
| Post Issue Communication - Certificate of Correction | 03 Nov, 2010 | US7811254 |
| Recordation of Patent Grant Mailed Critical | 12 Oct, 2010 | US7811254 |
US patents provide insights into the exclusivity only within the United States, but Alsuma is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Alsuma's family patents as well as insights into ongoing legal events on those patents.
Alsuma's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Alsuma's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 26, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Alsuma Generic API suppliers:
Sumatriptan Succinate is the generic name for the brand Alsuma. 29 different companies have already filed for the generic of Alsuma, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Alsuma's generic
Alternative Brands for Alsuma
Alsuma which is used for treating acute migraine attacks and cluster headache episodes., has several other brand drugs using the same active ingredient (Sumatriptan Succinate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Currax |
| ||
| Endo Operations |
| ||
| Teva Branded Pharm |
| ||
| Tonix Meds |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan Succinate, Alsuma's active ingredient. Check the complete list of approved generic manufacturers for Alsuma
About Alsuma
Alsuma is a drug owned by Meridian Medical Technologies Inc Sub King Pharmaceuticals Inc. It is used for treating acute migraine attacks and cluster headache episodes. Alsuma uses Sumatriptan Succinate as an active ingredient. Alsuma was launched by Meridian Medcl in 2010.
Approval Date:
Alsuma was approved by FDA for market use on 29 June, 2010.
Active Ingredient:
Alsuma uses Sumatriptan Succinate as the active ingredient. Check out other Drugs and Companies using Sumatriptan Succinate ingredient
Treatment:
Alsuma is used for treating acute migraine attacks and cluster headache episodes.
Dosage:
Alsuma is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | INJECTABLE | Discontinued | SUBCUTANEOUS |